Amicus Therapeutics (FOLD) Tops Q1 EPS by 4c ; Provides Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amicus Therapeutics (FOLD) PT Lowered to $13 at BofA Securities
May 10, 2024 5:27 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "FOLD reported 1Q Pombiliti+Opfolda (P&O) sales of $11mn and provided FY24 sales guidance of $62-67mn.... More
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
May 9, 2024 12:03 PM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $19.00 (from $20.00) while maintaining a Underweight rating.
The analyst comments "1Q earnings were in line with Street expectations for Galafold and below on Pombiliti + Opfolda (P+O). The company... More
